PIEL-L Latinoamericana Publicacion periodica en dermatologia | Fundada en 1998
Callander J1, Robson Y1, Ingram J2, Piguet V2.
Abstract
Clinically amyopathic dermatomyositis (CADM) affects a subset of 5-20% of dermatomyositis patients and is defined as the presence of cutaneous features of dermatomyositis without clinical muscle weakness for 6 months of more. There is no consensus on first line treatment for CADM and whether treatment should differ from treatment of classic dermatomyositis with muscle weakness. We carried out a systematic review of published literature about treatment of adult patients with CADM via embase, medline, CINAHL and clinical trials. gov databases on 17th